Preview Mode Links will not work in preview mode

GRACEcast


Oct 26, 2015

Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.